Browsing by Author "Llancaqueo Valeri, Marcelo"

Now showing items 1-4 of 4

    • Cytomegalovirus infections in cardiac transplant patients: An experience at a clinical hospital, University ... 
      Sepúlveda Morales, Luis; Llancaqueo Valeri, Marcelo; Zamorano, J.; Bermúdez, C.; Cortés, C. (2007)
      Background. Since cytomegalovirus (CMV) infects between 20% and 50% of heart transplant patients, we reviewed our experience in 7 cases of this infection. Methods. A prospective analysis of CMV infection was performed in ...
    • Diferencias genéticas en la disminución del colesterol por estatinas en pacientes chilenos con cardiopatia ... 
      Noriega Sepúlveda, Viviana Carolina; Pennanen Saavedra, Christian; Llancaqueo Valeri, Marcelo; Lavandero González, Sergio; Prieto Domínguez, Juan (Sociedad Chilena de Cardiología y Cirugía Cardiovascular, 2007)
      Las estatinas son fármacos de elección para el tratamiento de hipercolesterolemia. Sin embargo, dado que existe una considerable variabilidad interindividual en la reducción del colesterol, la evaluación farmacogenética ...
    • First case of simultaneous heart plus kidney transplantation in Chile: Case report 
      Sepúlveda Morales, Luis; Zamorano, J.; Cotera, A.; Núñez, N.; Llancaqueo Valeri, Marcelo; Bermúdez, C.; Castillo, R.; González, M.; Alvarez, F. (Elsevier, 2007)
      Advanced renal disease is a formal contraindication to heart transplantation, and heart failure may make a patient ineligible for kidney transplantation. The International Society of Heart and Lung Transplantation has ...
    • (TTA)n Polymorphism in 3-Hydroxy-3-Methylglutaryl-Coenzyme A and Response to Atorvastatin in Coronary Artery ... 
      Noriega Sepúlveda, Viviana Carolina; Pennanen Saavedra, Christian; Sánchez, P.; Chiong Lay, Mario; Llancaqueo Valeri, Marcelo; Lavandero González, Sergio; Prieto Domínguez, Juan (WILEY-BLACKWELL PUBLISHING, 2009-03)
      3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors have been used clinically for lowering total and low-density lipoprotein cholesterol. Interindividual pharmacological differences observed with this treatment have ...